Item 8.01 Other Events | ||||||||
| Item 9.01 Financial Statements and Exhibits | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EX-99.1: PRESS RELEASE | ||||||||
Table of Contents
Item 8.01 Other Events.
On September 22, 2008, Vion Pharmaceuticals, Inc. announced that it had entered into an agreement
with the Institut Paoli- Calmettes in Marseille, France to conduct a multi-center Phase I/II
clinical trial of laromustine (Cloretazine® (VNP40101M)) with remission-induction therapy in
patients aged 18-60 with previously untreated acute myelogenous leukemia (AML) and a poor prognosis
based on their cytogenetic profile. The Institut Paoli-Calmettes will be leading the study for the
French cooperative group GOELAMS (Groupe Ouest Est d’Etude des Leucémies et Autres Maladies du
Sang). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by
reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit 99.1 | Press release dated September 22, 2008. |